6.530USD-3.62%Mkt Cap: 1.01B USDP/E: —Last update: 2026-06-01
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.01B USD
Enterprise Value931.07M USD
Revenue (TTM)1.84M USD
Gross Profit-81.79M USD
Net Income (TTM)-115.18M USD
Revenue/Share0.0130 USD
Last Price6.530 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees140
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.63
PEG—
EV/EBITDA-8.00
EV/Revenue507.12
P/S573.18
P/B6.10
EPS (TTM)-0.82
EPS (Forward)-0.64
52W Range
2.24084% of range7.340
52W High7.340 USD
52W Low2.240 USD
Profitability
Gross Margin0.00%
Oper. Margin-14346.98%
EBITDA Margin0.00%
Profit Margin-4113.68%
ROE-60.80%
ROA-53.25%
Growth
Revenue Growth-81.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-92.92M USD
CapEx (TTM)1.11M USD
FCF Margin-2259.01%
FCF Yield-4.11%
Net Debt-121.29M USD
Net Debt/EBITDA1.04
Balance Sheet
Debt/Equity0.03
Current Ratio6.59
Quick Ratio6.28
Book Value/Sh1.107 USD
Cash/Share0.8060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)8.789 USD
Target Range4.100 USD – 12.00 USD
# Analysts9
Ownership
Shares Out.155.91M
Float146.13M
Insiders13.05%
Institutions78.93%
Short Interest
Short Ratio5.9d
Short % Float25.72%
Short % Out.20.67%
Shares Short32.23M
Short (prev mo.)35.09M
Technical
SMA 504.146 (+57.5%)
SMA 2003.401 (+92.0%)
Beta2.38
S&P 52W Chg27.94%
Avg Vol (30d)5.04M
Avg Vol (10d)3.87M
Technical Indicators
RSI (14)73.1
MACD0.4232
MACD Signal0.3789
MACD Hist.+0.0443
BB Upper6.458 USD
BB Middle5.445 USD
BB Lower4.433 USD
BB Width37.18%
ATR (14)0.5540 USD
Vol Ratio (20d)1.69x